This bill amends section 60A-2-204 of the Code of West Virginia to include crystalline polymorph psilocybin as a Schedule I drug, reflecting its approval by the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). This addition acknowledges the potential therapeutic uses of psilocybin and aligns state law with federal regulations. The bill does not propose any deletions from current law but expands the definition of Schedule I substances to incorporate this newly recognized form of psilocybin, ensuring that the legal framework governing controlled substances remains up-to-date with advancements in medical research.

Furthermore, the bill seeks to broaden the classification of controlled substances by including various synthetic cannabinoids, tryptamines, depressants, and stimulants that are not currently classified under federal schedules II, III, IV, and V. It specifies a range of chemical compounds, including different forms of methamphetamine and synthetic cathinones, while also addressing nomenclature to cover immediate precursors or derivatives. Additionally, the bill introduces a provision for the legal prescription, distribution, and marketing of organic psilocybin, specifically crystalline polymorph psilocybin known as COMP360, contingent upon FDA approval and DEA scheduling, thereby facilitating its use in legitimate medical contexts.

Statutes affected:
Introduced Version: 60A-2-204
Committee Substitute: 60A-2-204
Engrossed Committee Substitute: 60A-2-204